On Thursday, American Apparel Inc (NYSEMKT:APP)’s shares declined -5.20% to $0.559.
American Apparel Inc (APP) declared that it has commenced a $10.0 million “at-the-market” offering program.
Under the program, the Company may, from time to time and at its discretion, offer and sell shares of its common stock having an aggregate gross sales price of up to $10.0 million through Cowen and Company, LLC, which will serve as sales agent. The Company intends to use the net proceeds generated through the program for working capital and general corporate purposes.
Sales of common stock under the program will be made directly on the NYSE MKT, on any other existing trading market for the Company’s common stock or to or through a market maker. In addition, with the Company’s preceding written approval, sales may be made in negotiated transactions.
American Apparel, Inc. designs, manufactures, distributes, retails, and sells branded fashion basic apparel products, and clothing and accessories for women, men, children, and babies. It offers T-shirts, denim, sweaters, jackets, and accessories.
FibroGen Inc (NASDAQ:FGEN)’s shares dropped -9.36% to $21.39.
FibroGen Inc (FGEN) declared that it has received a $15 million milestone payment from AstraZeneca AB (“AstraZeneca”), triggered by the completion of roxadustat non-clinical carcinogenicity studies. In two separate two-year carcinogenicity studies, in rats and in mice, there was no evidence of a roxadustat-related effect on mortality or carcinogenicity.
Non-clinical carcinogenicity data are a standard component of novel small molecule drug development and are typically required by the U.S. Food and Drug Administration and other regulatory agencies as part of the drug approval process.
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that acts by stimulating the body’s natural pathway of red blood cell production, or erythropoiesis. Roxadustat is the first HIF-PHI to enter Phase 3 clinical development and represents a novel approach to the treatment of anemia in patients with chronic kidney disease (CKD), with the potential to address the considerable unmet medical need for an effective treatment for anemia that offers the convenience of oral administration and an improved safety profile as contrast to current standards of care.
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs.
At the end of Thursday’s trade, Synthesis Energy Systems, Inc. (NASDAQ:SYMX)‘s shares dipped -8.57% to $1.28.
Synthesis Energy Systems, Inc. (SYMX) stated financial and operating results for its fiscal 2015 third quarter, ended March 31, 2015.
During this past quarter we have gained good traction in China especially, where three clean coal gasification projects are under construction for Aluminum Corporation of China using seven total SES Gasification Systems. Our China joint venture, Tianwo-SES Clean Energy Technologies, is supplying a predictable $23 million of technology, proprietary equipment plus additional equipment related to the three gasification plants to the Innovative Coal Chemical Design Institute, or ICCDI. ICCDI is the turnkey contractor supplying all the engineering, construction and balance of plant equipment for the projects. These industrial syngas supply plants are in what we consider an emerging growth market of replacement gas, and they represent our first win by the Tianwo-SES joint venture. The construction by ICCDI is fast-tracked, in staged progression and two of the projects are predictable to be accomplished during this calendar year, with the third following in early 2016. Tianwo-SES reports a growing pipeline of seven similar prospective projects that may follow-on as the first of these projects start-up with good results.
Synthesis Energy Systems, Inc., a development stage energy and gasification technology company, provides various proprietary gasification technology systems and solutions to the energy and chemical industries worldwide.
Pacific Drilling SA (NYSE:PACD), ended its Thursday’s trading session with -9.13% loss, and closed at $4.10.
Pacific Drilling SA (PACD) declared net income for first-quarter 2015 of $51.7 million or $0.24 per diluted share, contrast to net income of $68.0 million or $0.32 per diluted share for fourth-quarter 2014. Net income for first-quarter 2014 was $22.2 million or $0.10 per diluted share.
First-Quarter 2015 Operational and Financial Commentary
Contract drilling revenue for first-quarter 2015 was $283.4 million, which comprised of $22.7 million of deferred revenue amortization, contrast to contract drilling revenue of $319.7 million for fourth-quarter 2014, which comprised of $25.9 million of deferred revenue amortization. Contract drilling revenue was influenced by the conclusion on Feb. 5, 2015, of the drilling contract for Pacific Mistral. During the three months ended March 31, 2015, our operating fleet achieved average revenue efficiencyof 95.2 percent.
Pacific Drilling S.A., together with its auxiliaries, operates as an offshore drilling contractor. It provides offshore drilling services to the oil and natural gas industry.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
